Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Aurinia Pharmaceuticals Inc. has been approved by the U.S. Food and Drug Administration to sell its drug for a severe form of lupus, a rare milestone for a Canadian biotechnology company.

The Victoria-based company said late Friday its drug Lupkynis, formerly known as voclosporin, had been approved for use in combination with immunosuppressive therapies to treat adults with lupus nephritis (LN), a variant of lupus that occurs when the immune system attacks the kidneys, often causing kidney failure and death. Until recently there was no FDA-approved treatment.

The FDA approval “marks a turning point for the lupus nephritis community,” Aurinia chief executive Peter Greenleaf said in a release. “We are thrilled to bring Lupkynis to the people impacted by this devastating condition.”

Story continues below advertisement

It’s a rare win for the Canadian drug development sector, which hasn’t produced an FDA-approved “major branded product … for a major disease from a truly Canadian innovation in well over a decade,” said Beni Rovinski, managing director with Toronto’s Lumira Ventures, an early backer.

Brian Bloom, CEO of Toronto-based health care boutique investment bank Bloom Burton, said fewer than 10 Canadian companies had received FDA approval for a novel drug, and “of the ones approved this has the potential to be one of the biggest sellers. This is absolutely monumental.”

Aurinia’s 357-patient study in December, 2019, found those who took voclosporin were nearly twice as likely as those on a placebo to show improved kidney health. “People with [LN] have desperately needed approved treatments to help them avoid irreversible kidney damage and the eventual need for a kidney transplant,” Steve Gibson, CEO of the Lupus Foundation of America, said in a release. He called Lupkynis “a much needed oral treatment option to address the challenges faced by people living with LN.”

Biotechnology developers often sell out before getting to commercialization, or license out go-to-market activities to pharmaceutical giants. While it has struck a deal with Japan’s Otsuka Pharmaceutical Co., Ltd, to commercialize voclosporin in Japan, Britain and seven European countries, Aurinia plans to sell the drug itself in the lucrative U.S. market, a rarity for a Canadian biotech company.

Aurinia has spent the past year gearing up to get its drug in market within days of FDA approval, expanding its ranks to 300 people, hiring sales and support staff to educate doctors and advocacy groups, ensure patient access and work on reimbursement. Despite that, Mr. Greenleaf said this month Aurinia would be open to a “table-clearing [takeover] offer.”

The company has raised nearly US$400-million from investors in the past 13 months and got a US$50-million payment from Otsuka; it will get more as the drug advances to market in Otsuka’s territories.

Aurinia was founded by three former executives of Victoria-based Aspreva Pharmaceuticals Corp.: Mr. Greenleaf’s predecessor Richard Glickman; chief business officer Michael Martin; and chief medical officer Neil Solomons. Aspreva had worked to develop a treatment for LN. It was sold in 2008 and the trio left to start Aurinia’s forerunner. Mr. Rovinski said Lumira invested $6-million in 2013 when “not a single other health care venture capitalist … would engage.”

Story continues below advertisement

Foreign investors followed after the group licensed voclosporin, originally developed to prevent organ-transplant rejections, from Edmonton’s Isotechnika Pharma Inc., then did a reverse takeover of Isotechnika. Aurinia listed on Nasdaq in 2015 and had a US$1.9-billion market cap as of Friday.

Lupus mainly affects women of childbearing age and of African, Latin American and Asian descent. Treatment has typically involved a mix of steroids and cancer drugs; side effects include loss of hair, vision and mobility, thinning of bone marrow, lethargy, nausea, anemia and depression.

Mr. Greenleaf has said Aurinia is not sure yet of its potential market size, though it believes its U.S. customer base could be in the high tens of thousands of people. The drug is expected to cost tens of thousands of dollars annually per patient, which may affect user numbers. Aurinia said it launched a support program to help patients “in navigating insurance and … medication costs.”

Aurinia has competition. GlaxoSmithKline PLC’s Benlysta – an intravenously-administered treatment for lupus – got FDA approval last month for use against LN. Roche Holding AG is also developing a LN drug. Aurinia stock closed Friday at US$14.86 on Nasdaq, down 2 per cent, in advance of the news.

Aurinia’s approval follows a historic 2020 for Canada’s biotech sector, which set records for public and private funding, including COVID-19 treatment developer AbCellera Biologics Inc.’s initial public offering last month.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies